AstraZeneca PLC [NASDAQ: AZN] closed the trading session at $64.12 on 03/08/23. The day’s price range saw the stock hit a low of $63.77, while the highest price level was $64.51. The company report on March 6, 2023 that ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
AstraZeneca and Daiichi Sankyo’s ENHERTU met prespecified criteria for objective response rate and duration of response.
Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.
The stocks have a year to date performance of -5.43 percent and weekly performance of -1.67 percent. The stock has been moved at 6.14 percent over the last six months. The stock has performed 0.94 percent around the most recent 30 days and changed -6.28 percent over the most recent 3-months.
If compared to the average trading volume of 4.89M shares, AZN reached to a volume of 3151785 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $76.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 05, 2023. The new note on the price target was released on September 15, 2022, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.17, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.49. The Price to Book ratio for the last quarter was 5.36, with the Price to Cash per share for the same quarter was set at 2.06. Price to Free Cash Flow for AZN in the course of the last twelve months was 45.76 with Quick ratio for the last quarter at 0.70.
AZN stock trade performance evaluation
AstraZeneca PLC [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.67. With this latest performance, AZN shares gained by 0.94% in over the last four-week period, additionally plugging by 6.14% over the last 6 months – not to mention a rise of 13.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 36.85, with the RSI for the last a single of trading hit 30.83, and the three-weeks RSI is set at 40.50 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 67.51, while it was recorded at 64.65 for the last single week of trading, and 64.27 for the last 200 days.
AstraZeneca PLC [AZN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +11.41 and a Gross Margin at +63.36. AstraZeneca PLC’s Net Margin is presently recorded at +7.41.
Return on Total Capital for AZN is now 7.69, given the latest momentum, and Return on Invested Capital for the company is 5.30. Return on Equity for this stock inclined to 8.93, with Return on Assets sitting at 3.38. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 78.93. Additionally, AZN Total Debt to Total Capital is recorded at 44.11, with Total Debt to Total Assets ending up at 30.30. Long-Term Debt to Equity for the company is recorded at 63.96, with the Long-Term Debt to Total Capital now at 35.75.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $31,968 per employee. Receivables Turnover for the company is 4.88 with a Total Asset Turnover recorded at a value of 0.46.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.90.
Earnings per share (EPS) analysis for AstraZeneca PLC [AZN] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 16.20%.
AstraZeneca PLC [AZN]: Insider Ownership positions
There are presently around $32,912 million, or 17.90% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 68,591,648, which is approximately -9.012% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 54,606,052 shares of the stock with an approximate value of $3.5 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $2.88 billion in AZN stock with ownership of nearly -1.375% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 485 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 36,159,093 shares. Additionally, 424 investors decreased positions by around 46,099,320 shares, while 226 investors held positions by with 431,030,186 shares. The mentioned changes placed institutional holdings at 513,288,599 shares, according to the latest SEC report filing. AZN stock had 164 new institutional investments in for a total of 7,036,619 shares, while 56 institutional investors sold positions of 4,174,406 shares during the same period.